Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01 mai 2019 16h47 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement...
Zogenix to Release First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 8
01 mai 2019 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...
Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for FINTEPLA® New Drug Application
08 avr. 2019 16h01 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it received a Refusal to...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01 avr. 2019 17h17 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement...
Zogenix to Present at Two Investor Conferences in April
25 mars 2019 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that members of management...
Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan
19 mars 2019 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into an...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01 mars 2019 16h51 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement...
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
28 févr. 2019 16h01 HE
|
Zogenix, Inc.
Completed rolling submission of an NDA to the U.S. FDA and an MAA to the EMA for FINTEPLA® for the treatment of seizures associated with Dravet syndrome in February 2019-- EMA has accepted MAA for...
Zogenix to Release Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on February 28
21 févr. 2019 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...
Zogenix to Present at the 8th Annual SVB Leerink Global Healthcare Conference
20 févr. 2019 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, President...